FDA Approves High-Dose Wegovy 7.2mg for Obesity in 2026
The FDA approved high-dose semaglutide 7.2mg (Wegovy) for obesity, showing 18.7% mean weight loss in Phase 3 trials amid new Trump administration drug pricing agreements.
By Sarah Tanaka
semaglutide
4 articles tagged "semaglutide"
FDA Targets Telehealth GLP-1 Compounders in 2026 Crackdown
FDA has warned 70+ telehealth companies over compounded GLP-1 drugs, with scrutiny now extending to affiliated medical groups and prescribing networks.
By Robert Kim
Wegovy Linked to Higher Ischemic Optic Neuropathy Risk
New FAERS analysis finds Wegovy carries nearly fivefold higher ischemic optic neuropathy risk vs. Ozempic, raising ocular safety concerns for GLP-1 drugs.
By Sarah Tanaka
Bimagrumab Plus Semaglutide for Obesity Management: Analysis of a Phase 2 Randomized Controlled Trial Demonstrating Enhanced Weight Reduction with Lean Mass Preservation
A phase 2 randomized controlled trial demonstrated that the combination of bimagrumab and semaglutide achieved superior weight reduction compared with semaglutide monotherapy while preserving lean muscle mass. The combination therapy resulted in a least squares mean weight loss of 17.8 kg versus 14.2 kg with semaglutide alone at 48 weeks.